Main Topics

Advances in disease biology and pathophysiology

AL amyloidosis

CAR T cells and other cellular therapies

Guidelines in specific clinical situations

Immunotherapy / Bispecific antibodies, Antibody drug conjugates, etc.

Minimal residual disease and disease assessment

Ongoing clinical trials and future trials

Options for refractory myeloma – sequencing of therapy in refractory disease

Outcome prediction and risk assessment

Smoldering myeloma, MGUS and precursor conditions

Therapy for non-transplant eligible patients

Treatment guidelines for young and fit patients

Small molecules and preliminary data

Waldenstrom macroglobulinemia